{"protocolSection":{"identificationModule":{"nctId":"NCT04891497","orgStudyIdInfo":{"id":"haojunwei5"},"organization":{"fullName":"Xuanwu Hospital, Beijing","class":"OTHER"},"briefTitle":"Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke","officialTitle":"Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2021-05","overallStatus":"WITHDRAWN","whyStopped":"There are no suitable patients","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-06-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2021-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2021-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-05-17","studyFirstSubmitQcDate":"2021-05-17","studyFirstPostDateStruct":{"date":"2021-05-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-10-24","lastUpdatePostDateStruct":{"date":"2023-10-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Xuanwu Hospital, Beijing","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in combination with intraarterial treatment in patients with Acute Ischemic Stroke."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Acute Ischemic Stroke","Immune Modulator","Dimethyl Fumarate","Intraarterial Treatment"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":0,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Intraarterial Treatment plus Dimethyl Fumarate","type":"EXPERIMENTAL","description":"Dimethyl fumarate 240mg orally twice daily for 3 consecutive days","interventionNames":["Drug: Dimethyl Fumarate"]},{"label":"Intraarterial Treatment plus placebo","type":"PLACEBO_COMPARATOR","description":"Placebo 240mg orally twice daily for 3 consecutive days","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Dimethyl Fumarate","description":"Dimethyl fumarate 240mg orally twice daily for 3 consecutive days","armGroupLabels":["Intraarterial Treatment plus Dimethyl Fumarate"]},{"type":"DRUG","name":"Placebo","description":"Placebo 240mg orally twice daily for 3 consecutive days","armGroupLabels":["Intraarterial Treatment plus placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"lesion volume","description":"measured by MRI","timeFrame":"day 1"},{"measure":"hemorrhage volume","description":"measured by MRI","timeFrame":"day 1"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day 1"}],"secondaryOutcomes":[{"measure":"lesion volume","description":"measured by MRI","timeFrame":"day3"},{"measure":"lesion volume","description":"measured by MRI","timeFrame":"day7"},{"measure":"lesion volume","description":"measured by MRI","timeFrame":"day90"},{"measure":"hemorrhage volume","description":"measured by MRI","timeFrame":"day3"},{"measure":"hemorrhage volume","description":"measured by MRI","timeFrame":"day7"},{"measure":"hemorrhage volume","description":"measured by MRI","timeFrame":"day14"},{"measure":"hemorrhage volume","description":"measured by MRI","timeFrame":"day90"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day3"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day7"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day14"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day90"},{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day1"},{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day3"},{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day7"},{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day14"},{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day90"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1.18-80 years old 2. NIHSS score\\>6 3. For the first stroke, MRI showed anterior circulation infarction 4. Patients who meet the mechanical thrombectomy treatment by MRI assessment within 24 hours\n\nExclusion Criteria:\n\n1. Patients receiving Alteplase thrombolysis\n2. Other diseases of the central nervous system\n3. There has been a neurological disability in the past (mRS score\\>2)\n4. Difficulty swallowing\n5. Arrhythmia, atrioventricular block\n6. Use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs\n7. Macular edema\n8. Magnetic resonance angiography shows vertebra-basilar artery obstruction\n9. Hemorrhagic stroke\n10. Patients who are known to have hypersensitivity to dimethyl fumarate or any excipients of this product\n11. Pregnant and lactating women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069462","term":"Dimethyl Fumarate"}],"ancestors":[{"id":"D000003879","term":"Dermatologic Agents"},{"id":"D000007166","term":"Immunosuppressive Agents"},{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M2854","name":"Immunomodulating Agents","relevance":"LOW"},{"id":"M431","name":"Dimethyl Fumarate","asFound":"Periodontal treatment","relevance":"HIGH"},{"id":"M6764","name":"Dermatologic Agents","relevance":"LOW"},{"id":"M9902","name":"Immunosuppressive Agents","relevance":"LOW"},{"id":"M9891","name":"Immunologic Factors","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Derm","name":"Dermatologic Agents"}]}},"hasResults":false}